Karyopharm Therapeutics

Karyopharm Therapeutics is driven by the extraordinary strength and courage of the patients we serve. What began as a visionary, founder-led start-up has evolved into a global leader in oncology innovation committed to transforming cancer treatment with bold, cutting-edge therapies. Our pioneering SINE (Selective Inhibition of Nuclear Export) technology targets cancer cells in a revolutionary way, offering hope for patients with both blood cancers and solid tumors. Headquartered in Newton, Massachusetts, we’ve expanded our global presence with our first FDA approved product now available across the U.S., Europe and Asia. Building on our success in multiple myeloma, Karyopharm is advancing a promising clinical pipeline that extends beyond oncology, with innovative compounds also targeting rare diseases. As we continue leading in oncology innovation, we are not just about advancing science; we are inspired daily by the patients we serve and fueled by the energy and resilience required to face challenges head-on. From our beginnings rooted in remarkable science to our position as a commercial-stage leader, Karyopharm is shaping a future that aims to redefine cancer care and improve lives.